|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Engineering imaging probes and molecular machines for nanomedicine显示文摘Nanomedicine is an emerging field that integrates nanotechnology, biomolecular engineering, life sciences and medicine; it is expected to produce major breakthroughs in medical diagnostics and therapeutics. Due to the size-compatibility of nano-scale structures and devices with proteins and nucleic acids, the design, synthesis and application of nanoprobes, nanocarriers and nanomachines provide unprecedented opportunities for achieving a better control of biological processes, and drastic improvements in disease detection, therapy, and prevention. Recent advances in nanomedicine include the development of functional nanoparticle based molecular imaging probes, nano-structured materials as drug/gene carriers for in vivo delivery, and engineered molecular machines for treating single-gene disorders. This review focuses on the development of molecular imaging probes and engineered nucleases for nanomedicine, including quantum dot bioconjugates, quantum dot-fluorescent protein FRET probes, molecular beacons, magnetic and gold nanoparticle based imaging contrast agents, and the design and validation of zinc finger nucleases (ZFNs) and TAL effector nucleases (TALENs) for gene targeting. The challenges in translating nanomedicine approaches to clinical applications are discussed. | TONG Sheng CRADICK Thomas J MA Yan DAI ZhiFei BAO Gang | 2012 | Science China(Life Sciences)2012，55，10： | 2 |
| 2 | DesigningandtestingtheactivitiesofTALeffectornucleases显示文摘 | Lin Y Cradick TJ Bao G | 2014 | Methods Mol Biol2014，1114，： | 1 |
| 3 | Defining critical residues in the epitope for HIV-neutralizing monoclonal antibody using phage display and peptide array technologies 显示文摘 | Jellis CL Cradick TJ Rennert P | 1993 | Gene1993，137，1： | 1 |
| 4 | CRISPR/Cas9 systems tar- geting β-globin and CCR5 genes have substantial off-target activity 显示文摘 | Cradick TJ Fine EJ Antico CJ | 2013 | Nucleic Acids Research2013，41，20： | 1 |
| 5 | Seamless modification of wild-type induced pluripotent stemcells to the natural CCR5A32 mutation confers resistance toHIV infection 显示文摘 | Ye L Wang J Beyer Al Teque F Cradick TJ Qi Z Chang JC Bao G Muench MO Yu J Levy JA Kan YW | 2014 | Proc Natl Acad Sci USA2014，111，26： | 1 |
| 6 | Defining critical residues in the epitope for a HIV-neutralizing monoclonal antibody using phage display and peptide array technologies显示文摘 | Jellis CK Cradick TJ Rennert P | 1993 | Gene1993，137，1： | 1 |
| 7 | Engineering imaging probes and molecular machines for nanomedieine 显示文摘 | Sheng Tong Thomas J Cradick Yan Ma | 2012 | Sci China Life Sci2012，55，10： | 1 |
| 8 | Zinc-finger nucleases as a novel therapeutic strategy for targeting hepatitis B virus DNAs显示文摘 | Cradick T J Keck K Bradshaw S | 2010 | Molecular Thera- py2010，18，： | 1 |
| 9 | Defining critical residues in the epitope for HIV-neutralizing monoclonal antibody using phage display and peptide array technologies 显示文摘 | Jellis CL Cradick TJ Rennert P | 1993 | Gene1993，137，1： | 1 |
| 10 | Defining critical residues in the epitope for HIV neutralizing monoclonal antibody using phage display and peptide array technologies显示文摘 | Jellis CL Cradick TJ Rennert P | 1993 | Gene1993，137，1： | 1 |
| 11 | Zinc-finger nucleases as a novel therapeutic strategy for targeting hepatitis B virus DNAs 显示文摘 | Cradick T J Keck K Bradshaw S | 2010 | Mol Ther2010，18，5： | 1 |
| 12 | Seamless modification of wild-type induced pluripotent stemcells to the natural CCR5A32 mutation confers resistance toHIV infection 显示文摘 | Ye L Wang J Beyer AI Teque F Cradick TJ Qi Z Chang JC Bao G Muench MO Yu J Levy JA Kan YW | 2014 | Proc Natl Acad Sci USA2014，111，26： | 1 |
| 13 | CRISPR/Cas9 systems targeting β-globin and CCR5 genes have substantial off-target activity显示文摘 | Thomas J. Cradick Eli J. Fine Christopher J. Antico Gang Bao | 2013 | Nucleic Acids Research2013，，： | 1 |
| 14 | COSMID: A Web-based Tool for Identifying and Validating CRISPR/Cas Off-target Sites 显示文摘 | Cradick TJ Qiu P Lee CM | 2014 | Mol Ther Nucleic Acids2014，3，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员